Privia Health Group, Inc. (NASDAQ:PRVA) disclosed in a Securities and Exchange Commission Form 4 that Executive Vice President and Chief Financial Officer David Mountcastle sold 6,391 shares of common stock on March 16, 2026. The shares were sold at $22.11 each, producing total proceeds of $141,305.
The filing specifies that the sale was executed to satisfy tax withholding obligations tied to the vesting and settlement of performance stock units. At the time of the transaction the company’s stock was trading at $21.59 and Privia Health carried a market capitalization of $2.67 billion.
After completing the sale, Mountcastle retains direct ownership of 220,413 shares of Privia Health common stock. He also holds an indirect interest in 8,695 shares through his spouse, according to the Form 4.
Company valuation and research notes
Market research referenced in public disclosures identifies PRVA among names appearing on a list of the most undervalued stocks, based on InvestingPro analysis. The same research service offers a Pro Research Report that covers PRVA along with more than 1,400 U.S. equities for investors seeking a deeper dive.
Recent financial performance and analyst reaction
Privia Health reported a notably strong fourth quarter for fiscal 2025. The company posted earnings per share of $0.99, well above the consensus projection of $0.04, representing a 2,375% surprise. Quarterly revenue reached $541.17 million, topping the expected $515.86 million.
Following the release, Jefferies raised its price target for Privia Health to $32 while maintaining a Buy rating. Piper Sandler also increased its price target to $36 and kept an Overweight rating. Both firms cited the strong fourth-quarter results and supportive guidance for 2026.
Analysts highlighted the company’s momentum across several operational metrics, naming Implemented Providers, Revenue, Care Margin, and Adjusted EBITDA as areas that drove the positive reaction. These developments have contributed to a broadly favorable analyst outlook on the company’s near-term growth trajectory.
Summary takeaways
- Mountcastle’s sale was a tax-driven transaction tied to vested performance stock units and was disclosed via Form 4.
- Privia Health’s Q4 2025 results substantially exceeded expectations on both EPS and revenue, prompting higher price targets from major brokerages.
- Independent research flagged PRVA as appearing on an undervalued list and noted the availability of a detailed Pro Research Report covering the company and 1,400+ U.S. equities.
Investors and market participants monitoring insider transactions and analyst responses will likely weigh the tax-related nature of the CFO sale alongside the company’s recent operational and financial strength.